Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis.

Abstract

We assessed the efficacy of topical cyclosporin 0.05% ophthalmic emulsion versus tobramycin 0.3%/dexamethasone 0.1% in patients with posterior blepharitis. Posterior blepharitis improved significantly from the initial study visit with both cyclosporin treatment and tobramycin/dexamethasone. Cyclosporin provided greater improvements in Schirmer's scores (P < 0.001) and tear break-up time (P = 0.018) than tobramycin/dexamethasone after 12 weeks of treatment. Eyelid health also improved in both groups, but the mean improvement in meibomian gland secretion quality was significantly greater with cyclosporin than with tobramycin/dexamethasone (P = 0.015). Moreover, a higher percentage of patients in the cyclosporin treatment group had improvements in symptoms of blurred vision, burning, and itching and more cyclosporin-treated patients experienced resolution of lid telangiectasia. The findings in this prospective study suggest that posterior blepharitis can be more effectively treated with cyclosporin than with tobramycin/dexamethasone. These findings should be further evaluated in large-scale, controlled, clinical trials.

• Authors: Michael Rubin, Sanjay N Rao
• Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (J Ocul Pharmacol Ther) Vol. 22 Issue 1 Pg. 47-53 (Feb 2006) ISSN: 1080-7683 [Print] United States
• PMID: 16503775 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Anti-Inflammatory Agents
• Immunosuppressive Agents
• Ophthalmic Solutions
• Dexamethasone
• Cyclosporine
• Tobramycin

Topics

• Administration, Topical
• Anti-Bacterial Agents (therapeutic use)
• Anti-Inflammatory Agents (therapeutic use)
• Blepharitis (drug therapy, pathology)
• Cyclosporine (administration & dosage)
• Dexamethasone (therapeutic use)
• Female
• Humans
• Immunosuppressive Agents
• Male
• Middle Aged
• Ophthalmic Solutions
• Prospective Studies
• Tears (metabolism)
• Tobramycin (therapeutic use)
• Treatment Outcome